Treatment algorithm for myelodysplastic syndrome in patients with very low, low, or intermediate risk profile (1) (adapted from [5–7]). | Dark olive boxes: approved treatment in Europe; red boxes: recommended but not approved; EPO, erythropoietin | Germing, U., Kobbe, G., Haas, R., & Gattermann, N. (2013). Myelodysplastic syndromes: diagnosis, prognosis, and treatment. Deutsches Arzteblatt International, 110(46), 783–790. https://doi.org/10.3238/arztebl.2013.0783

Leave a Reply